ArticleFrontiers in immunology2026
Uncovering cellular perturbations and key mediator communications in liver cancer using single-cell RNA sequencing.
Article in Frontiers in immunology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
Abstract
Liver cancer ranks as the sixth most common malignancy and the third leading cause of cancer-related death, with hepatocellular carcinoma (HCC) accounting for over 80% of cases. Its aggressive nature and late diagnosis severely limit treatment options. Tumor heterogeneity and a complex immune microenvironment further impede immunotherapy efficacy. By analyzing HCC data, we identified an epithelial subtype marked by proliferative capacity, invasiveness, and metabolic reprogramming, particularly in sugar and lipid metabolism. This subtype contributes to immune microenvironment complexity through interactions with Lipid-Associated tumor associated macrophage cells (LA_TAMs) that are linked to disease progression. A prognostic model (Tumor Epithelial Feature Signature, TEFS) revealed UAP1L1 as a computationally predicted key modulator of the cell cycle and extracellular matrix remodeling. Functional validation confirmed its clinical relevance and oncogenic role. These findings link epithelial features, metabolic dysregulation, and immune dynamics in HCC, identifying UAP1L1 as a potential target to enhance immunotherapy efficacy.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.